Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia

Journal of Clinical Pharmacology

Volumn 44, Issue 10, 2004, Pages 1173-1184

  Harvey, Anne T ^a,b,e   Flockhart, David ^c   Gorski, J Christopher ^c   Greenblatt, David J ^d   Burke, Michael ^b   Werder, Steve ^a,b   Preskorn, Sheldon H ^a,b  

^a University of Kansas School of Medicine Wichita Psychiatric Research Institute   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Via Christi Research Inc ^*  (United States)

Author keywords

Haloperidol; Intramuscular; Lorazepam; QT interval; Schizophrenia

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; ATORVASTATIN; BENZATROPINE; BUSPIRONE; CITALOPRAM; CLONAZEPAM; CONJUGATED ESTROGEN; COTRIMOXAZOLE; DIPHENHYDRAMINE; FELODIPINE; GABAPENTIN; HALOPERIDOL; IBUPROFEN; LANSOPRAZOLE; LEVOTHYROXINE SODIUM; LORATADINE; LORAZEPAM; OLANZAPINE; PAROXETINE; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; ROFECOXIB; TIOTIXENE; TOLTERODINE; TRAZODONE; UNINDEXED DRUG; VITAMIN;

ADULT; AGGRESSION; AGITATION; ARTICLE; CALCULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FATALITY; DRUG RESPONSE; ELECTROCARDIOGRAPHY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEART RATE; HUMAN; MALE; NONHUMAN; PROLACTIN BLOOD LEVEL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCHIZOPHRENIA; SINGLE BLIND PROCEDURE; TORSADE DES POINTES;

ADULT; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; ELECTROCARDIOGRAPHY; FEMALE; HALOPERIDOL; HUMANS; INJECTIONS, INTRAMUSCULAR; LONG QT SYNDROME; LORAZEPAM; MALE; MIDDLE AGED; SCHIZOPHRENIA;

EID: 4444352800     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004267807     Document Type: Article

References (38)

1. Currier GW: Atypical antipsychotic medications in the psychiatric emergency service. J Clin Psychiatry 2000;61(Suppl. 14):21-26.
2. Treatment of agitation in older persons with dementia: the Expert Consensus Panel for agitation in dementia. Postgrad Med 1998; Apr(Spec No):1-88.
3. Classman AH, Bigger JT Jr: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774-1782.
4. Suessbrich H, Schonherr R, Heinemann SH, Attali B, Lang F, Busch AE: The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol 1997;120:968-974.
5. Sanguinetti MC, Jiang C, Curran ME, Keating MT: A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995;81:299-307.
6. Drici M-D, Wang W, Liu X-K, Woosley RL, Flockhart DA: Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharm 1998;18:477-481.
7. max. Poster presented at the 155th annual meeting of the American Psychiatric Association (APA), Philadelphia, May 18-23, 2002.
8. Pfizer, Inc.: FDA briefing document for Zeldox Capsules (Ziprasidone HCl), July 19, 2000. Accessed April 28, 2003, from www.fda. gov.ohrms/dockets/ ac/00/backgrd/3619b1a.pdf
9. Desai M, Tanus-Santos JE, Li L, Gorski JC, Arefayene M, Liu Y, et al: Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. Pharmacogenetics J 2003;3:105-113.
10. Hatta K, Takahashi T, Nakamura H, Yamashiro H, Asukai N, Matsuzaki I, et al: The association between intravenous haloperidol and prolonged QT interval. J Clin Psychopharmacol 2001;21:257-261.
11. Fulop G, Phillips RA, Shapiro AK, Gomes JA, Shapiro E, Nordlie JW: ECG changes during haloperidol and pimozide treatment of Tourette's disorder. Am J Psychiatry 1987;144:673-675.
12. Cressman WA, Bianchine JR, Slotnick VB, Johnson PC, Plostnicks J: Plasma level profile of haloperidol in man following intramuscular administration. Eur Clin Pharmacol 1974;7:99-103.
13. Bianchetti G, Zarifian E, Poirier-Littre MF, Morselli PL, Deniker P: Influence of route of administration on haloperidol plasma levels in psychotic patients. Int J Clin Pharmacol Ther Toxicol 1980:18:324-327.
14. Greenblatt DJ, Joyce TH, Comer WH, Knowles JA, Shader RI, Kyriakopoulos AA, et al: Clinical pharmacokinetics of lorazepam. Clin Pharmacol Ther 1976;21:222-230.
15. Kirch W, Gorg KG: Clinical pharmacokinetics of atenolol-a review. Eur J Drug Metab Pharmacokinet 1982;7:81-91.
16. Malik M: Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 2001; 12:411-420.
17. European Agency for the Evaluation of Medicinal Products: Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products, 1997. Accessed April 18, 2003, from www.emea.eu.int/pdfs/human/swp/ 098696en.pdf
18. Greenblatt DJ, von Moltke LL, Ehrenberg BL, Harmatz JS, Corbett KE, Wallace DW, et al: Kinetics and dynamics of lorazepam during and after continuous intravenous infusion. Crit Care Med 2000;28: 2750-2757.
19. Markianos M, Sakellariou G, Bistolaki E: Prolactin responses to haloperidol in drug-free and treated schizophrenic patients. J Neural Transm Gen Sect 1991;83:37-42.
20. Langer G, Sachar EJ, Halpern FS, Gruen PH, Solomon M: The prolactin response to neuroleptic drugs: a test of dopaminergic blockade: neuroendocrine studies in normal men. J Clin Endocrinol Metab 1977;45:996-1002.
21. Presentation of Dr. Jeremy Ruskin to the FDA, CDER, Anti-infective Drugs Advisory Committee, April 26, 2001. Accessed April 28, 2003, from www.fda.gov/ohrms/dockets/ac/01/transcripts/ 3746t1.html; www.fda.gov/ohrms/ dockets/ac/01/slides/3746s_01_ Ruskin/index.htm
22. Allen MH: Managing the agitated psychotic patient: a reappraisal of the evidence. J Clin Psychiatry 2000;61(Suppl. 14):11-20.
23. Lin K-M, Poland RE, Lau JK, Rubin RT: Haloperidol and prolactin concentrations in Asians and Caucasians. J Clin Psychopharmacol 1988;8:195-201.
24. Rubin RT, Hays SE: Variability of prolactin response to intravenous and intramuscular haloperidol in normal adult men. Psychopharmacology 1979;61:17-24.
25. Benet LZ, Mitchell JR, Sheiner LB: Pharmacokinetics: the dynamics of drug absorption, distribution and elimination, in: Gilman AG, Rail TW, Nies AS, Taylor P (eds.), Goodman and Gilman's: The Pharmacological Basis of Therapeutics. 8th ed. New York: Pergamon, 1990;3-32.
26. Schlyer DJ, Volkow ND, Fowler JS, Wolf AP, Shiue CY, Dewey SL, et al: Regional distribution and kinetics of haloperidol binding in human brain: a PET study with [18F]haloperidol. Synapse 1992;11: 10-19.
27. Kapur S, Zipursky R, Jones C, Remington G, Houle S: Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-520.
28. Hemsley KM, Crocker AD: Changes in muscle tone are regulated by D1 and D2 dopamine receptors in the ventral striatum and D1 receptors in the substantia nigra. Neuropsychopharmacology 2001;25:514-526.
29. Bernardo M, Parellada E, Lomena F, Catafau AM, Font M, Gomez JC, et al: Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint. Psychiatry Res 2001;107:87-97.
30. Eckardt L, Breithardt G, Haverkamp W: Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation. JPharmacol Exp Ther 2002;300:64-71.
31. Kobayashi Y, Cavallotti D, Ricci A, Amenta F: Localization of dopamine D2-like receptors in pulmonary artery of the human and rabbit but not of the rat. Eur J Pharmacol 1994;261:229-236.
32. Cavallotti D, Nuti F, Bruzzone P, Mancone M: Age-related changes in dopamine D2 receptors in rat heart and coronary vessels. Clin Exp Pharmacol Physiol 2002;29:412-418.
33. Bruzzone P, D'Andrea V, Motta C, Cavallotti D: Occurrence of dopaminergic D(2) receptors within rabbit pulmonary circulation. Pulm Pharmacol Ther 2002;15:393-398.
34. Gomes P, Soares Da Silva P: D2-like receptor-mediated inhibition of Na+-K+-ATPase activity is dependent on the opening of K+ channels. Am J Physiol Renal Physiol 2002;283:F114-F123.
35. Katrak PH: Stroke patients: do they have a predilection for extra-pyramidal side effects from amiodarone? Arch Phys Med Rehabil 1999;80:112-114.
36. CORDARONE package insert, Wyeth-Ayerst, Philadelphia.
37. Monassier L, Bousquet P: Sigma receptors: from discovery to highlights of their implications in the cardiovascular system. Fundam Clin Pharmacol 2002;16:1-8.
38. Jeanjean AP, Mestre M, Maloteaux JM, Laduron PM: Is the sigma-2 receptor in rat brain related to the K+ channel of class III anti-arrhythmic drugs? Eur J Pharmacol 1993;241:111-116.